Benralizumab Matches Mepolizumab for Rare Vasculitis
WASHINGTON — Treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), the randomized MANDARA trial showed. Among 140 patients receiving standard therapy, the adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group, […]
Neurologic Events After COVID-19 Vaccines Assessed
All patients hospitalized with new or relapsing neurologic events after SARS-CoV-2 vaccination at a New York tertiary hospital had one or more risk factors for their neurologic condition, a prospective study showed. The most prominent neurologic index events in these vaccinated patients were ischemic stroke (37.7%), encephalopathy (32.6%), seizure (15.9%), and intracranial hemorrhage (ICH; 9.4%), […]
Anti-CD20 Agent Gains Approval for Multiple Sclerosis
Ublituximab (Briumvi), a monoclonal antibody targeting CD20, was approved for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, TG Therapeutics announced. The FDA’s decision was based on two identical phase III trials of people with relapsing MS, ULTIMATE I and ULTIMATE II. At 96 weeks, ublituximab […]
Cervical Cord Atrophy Predicts Silent MS Progression
Spinal cord atrophy predicted disease progression in people with relapsing multiple sclerosis (MS), a single-center observational study showed. A 1% faster cervical cord atrophy rate was associated with 69% (P<0.0001) shorter time to silent clinical progression and a 53% (P<0.0001) shorter time to secondary progressive MS (SPMS) conversion, reported Antje Bischof, MD, of University Hospital […]